Literature DB >> 8758003

Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals.

J C Luxton1, A J Rowe, J C Cridland, T Coletart, P Wilson, P S Shepherd.   

Abstract

The levels of proliferative T cell responses to peptides representing the human papillomavirus type 16 (HPV-16) E7 protein have been measured using short-term T cell lines derived from peripheral blood of healthy women and those with cervical dysplasias and carcinoma of the cervix. In healthy individuals 47 percent (7/15) responded predominantly to the N- and C-terminal regions of the protein and 6/7 responders were to a single peptide between amino acids 80-94. In comparison 29 percent (9/31) of women with cervical dysplasia responded to HPV-16 E7, with a significantly reduced response to both the N- and C-terminal regions (P = 0.03 and 0.038, respectively). A higher proportion of responders was found in patients with high grade lesions (56 percent, 5/9) versus those with atypical or low grade histology (20 percent, 4/20) and the response to a single peptide between amino acids 75-94 was also increased in this patient group (P = 0.044). This may be a reflection of higher levels of current or previous exposure to HPV-16 in patients with high grade lesions. Correlation of T cell responses with HPV DNA type (detected by PCR of cervical biopsy tissue) showed that 3/9 (33 percent) HPV-16 DNA-positive individuals responded. This suggests that E7 may not be the dominant target of the immune response or that the response to E7 is down-regulated in these patients. In addition 4/18 (22 percent) HPV-16 DNA-negative individuals responded, suggesting that their T cells may have been primed by previous exposure to HPV-16 or that a cross-reactive response was detected. Proliferative T cell responses to both HPV-16 E7 and L1 were reduced in women with cervical carcinoma in comparison to those with cervical dysplasia and healthy controls. The observed down-regulation of responses to HPV-16 E7 in women with cervical dysplasia and cervical carcinoma may reflect an altered functional balance between subsets of T helper cells in HPV-16 infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758003     DOI: 10.1099/0022-1317-77-7-1585

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Overcoming Barriers to Cervical Cancer Screening Among Asian American Women.

Authors:  Carolyn Y Fang; Grace X Ma; Yin Tan
Journal:  N Am J Med Sci (Boston)       Date:  2011

3.  Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts.

Authors:  K Hong; C E Greer; N Ketter; G Van Nest; X Paliard
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

Review 4.  ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.

Authors:  Lori Cory; Christina Chu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia.

Authors:  Carolyn Y Fang; Suzanne M Miller; Dana H Bovbjerg; Cynthia Bergman; Mitchell I Edelson; Norman G Rosenblum; Betsy A Bove; Andrew K Godwin; Donald E Campbell; Steven D Douglas
Journal:  Ann Behav Med       Date:  2008-02-13

6.  Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

Authors:  Mayumi Nakagawa; Raphael Viscidi; Ian Deshmukh; Maria Da Costa; Joel M Palefsky; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

7.  Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types.

Authors:  O Martin Williams; Keith W Hart; Eddie C Y Wang; Colin M Gelder
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Authors:  I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

Review 9.  Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.

Authors:  Joseph G Skeate; Andrew W Woodham; Mark H Einstein; Diane M Da Silva; W Martin Kast
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

10.  The influence of human papillomavirus type and HIV status on the lymphomononuclear cell profile in patients with cervical intraepithelial lesions of different severity.

Authors:  Maria Alice G Gonçalves; Edson G Soares; Eduardo A Donadi
Journal:  Infect Agent Cancer       Date:  2009-08-18       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.